Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is listed as the manufacturer on 1 FDA drug label records covering 1 distinct active ingredients predominantly human prescription drug products.
About Puma Biotechnology, Inc.
Puma Biotechnology, Inc. is named as the labeler on 1 FDA drug label records. Its catalogue spans 1 distinct active ingredients, led by NERATINIB. Most of these labels are human prescription drug products. Labelling across this portfolio most often references: breast cancer, treatment adult, extended adjuvant, advanced metastatic, single agent, received two, prior anti-her, based regimens. Use the table below to identify a specific product, then open it for full indications, dosage and warnings as filed with the FDA.
Active ingredients in this portfolio
| Active ingredient | Products |
|---|---|
| NERATINIB | 1 |
Dosage forms and routes
| Dosage form | Products | Route | Products |
|---|---|---|---|
| — | — | ORAL | 1 |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
| — | — | — | — |
FDA drug products from Puma Biotechnology, Inc.
| Brand name | Generic | Type | Route |
|---|---|---|---|
| Nerlynx | NERATINIB | HUMAN PRESCRIPTION DRUG | ORAL |
Frequently asked questions
How many FDA drug products does Puma Biotechnology, Inc. make?
1 FDA drug label records name Puma Biotechnology, Inc. as the manufacturer, covering 1 distinct active ingredients.
What active ingredients does Puma Biotechnology, Inc. produce?
The most frequent active ingredients in this portfolio are NERATINIB.
Are Puma Biotechnology, Inc. products prescription or over-the-counter?
The largest share of this company’s labels are human prescription drug products; check each product page for its own marketing status.
Does this page list prices or where to buy?
No. This is a labelling reference built from FDA data. It does not sell, price or recommend any medicine.
Labelling data reproduced from FDA Structured Product Labelling for identification only. This site does not sell, price or recommend any medicine.